Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | Harnessing apoptosis in AML

Marina Konopleva • 2 Sep 2020
SOHO 2020
Acute Myeloid Leukemia Leukemia Azacitidine Decitabine Gilteritinib Venetoclax

Marina Konopleva, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, TX, outlines clinical updates evaluating the use of agents targeting apoptotic signals in acute myeloid leukemia (AML), including venetoclax, a BCL-2 inhibitor, in combination with azacitidine, as well as triplet combinations with FLT3 inhibitors or novel monoclonal antibodies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Marina Konopleva

2:41
Advancements in AML: an update from ASH 2023
Marina Konopleva • 8 Dec 2023
1:36
The synergetic mechanism of pivekimab sunirine and venetoclax and its potential for treating AML
Marina Konopleva • 8 Dec 2023
1:03
10-day ASTX727 (decitabine/cedazuridine) with venetoclax in the treatment of R/R AML
Marina Konopleva • 8 Dec 2023
1:17
Targeting mitochondrial metabolism to eradicate MRD in AML
Marina Konopleva • 8 Dec 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals